Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen's Prolia Gains First Regulatory Win, With Market Approval in Europe

Executive Summary

The European Commission has finally granted a marketing authorization for Amgen's bone loss therapy, Prolia (denosumab), five months after CHMP issued a positive opinion

You may also be interested in...

Aranesp Sales Continue To Slide But Amgen Reports A Solid Year

During its fourth-quarter 2009 earnings call, Amgen also reported it has re-filed denosumab for osteoporosis with FDA.

Amgen’s Prolia Bone Drug Is Poised For Clearance In Europe

Two out of three indications ain’t bad: Panel votes for use in post-menopausal osteoporosis and bone loss in prostate cancer.

GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care

Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts